HPA001032

antibody from Atlas Antibodies

Targeting: PDCD4 H731

Western blot (Data presented on provider website)

Immunohistochemistry (Supportive data in Antibodypedia)

Antibody Data

Product number

HPA001032

Provider

Atlas Antibodies

Proper citation

Atlas Antibodies Cat#HPA001032, RRID:AB_1079586

Product name

Anti-PDCD4

Antibody type

Polyclonal

Description

Polyclonal Antibody against Human PDCD4, Gene description: programmed cell death 4 (neoplastic transformation inhibitor), Alternative Gene Names: H731, Validated applications: IHC, WB, Uniprot ID: Q53EL6, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

100 µl

Concentration

0.1 mg/ml

Storage

Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Handling

The antibody solution should be gently mixed before use.

References

Submitted references

Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma.

Galuppini F, Fassan M, Bertazza L, Barollo S, Cascione L, Watutantrige-Fernando S, Lazzarin V, Simonato P, Vianello F, Rugge M, Mian C, Pennelli G
Cancer management and research 2019;11:7845-7855

---

MiR-21 over-expression and Programmed Cell Death 4 down-regulation features malignant pleural mesothelioma.

Nicolè L, Cappellesso R, Sanavia T, Guzzardo V, Fassina A
Oncotarget 2018 Apr 3;9(25):17300-17308

---

Programmed cell death 4 nuclear loss and miR-21 or activated Akt overexpression in esophageal squamous cell carcinogenesis

Fassan M, Realdon S, Pizzi M, Balistreri M, Battaglia G, Zaninotto G, Ancona E, Rugge M
Diseases of the Esophagus 2012;25(3):263-268

---

MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome.

Mian C, Pennelli G, Fassan M, Balistreri M, Barollo S, Cavedon E, Galuppini F, Pizzi M, Vianello F, Pelizzo MR, Girelli ME, Rugge M, Opocher G
Thyroid : official journal of the American Thyroid Association 2012 Sep;22(9):890-6

---

PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis

Fassan M, Pizzi M, Giacomelli L, Mescoli C, Ludwig K, Pucciarelli S, Rugge M
Virchows Archiv 2011;458(4):413-419

---

Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis.

Fassan M, Pizzi M, Battaglia G, Giacomelli L, Parente P, Bocus P, Ancona E, Rugge M
Journal of clinical pathology 2010 Aug;63(8):692-6

---

MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets

Baffa R, Fassan M, Volinia S, O'Hara B, Liu C, Palazzo J, Gardiman M, Rugge M, Gomella L, Croce C, Rosenberg A
The Journal of Pathology 2009;219(2):214-221

---

Tissue profiling of the mammalian central nervous system using human antibody-based proteomics.

Mulder J, Björling E, Jonasson K, Wernérus H, Hober S, Hökfelt T, Uhlén M
Molecular & cellular proteomics : MCP 2009 Jul;8(7):1612-22

---

From Gene Expression Analysis to Tissue Microarrays

Ek S, Andréasson U, Hober S, Kampf C, Pontén F, Uhlén M, Merz H, Borrebaeck C
Molecular & Cellular Proteomics 2006;5(6):1072-1081

Immunohistochemistry

Supportive validation

Submitted by

Atlas Antibodies (provider)

Enhanced method

Orthogonal validation

Main image

Experimental details

Immunohistochemistry analysis in human breast and skeletal muscle tissues using HPA001032 antibody. Corresponding PDCD4 RNA-seq data are presented for the same tissues.

Sample type

Human

Protocol

Protocol

Orthogonal method

Orthogonal validation of protein expression using IHC by comparison to RNA-seq data of corresponding target in high and low expression tissues.

Show more